Skip to main
BIOX

BIOX Stock Forecast & Price Target

BIOX Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bioceres Crop Solutions Corp demonstrates a robust financial outlook due to its solid performance outside Argentina, particularly in the Crop Protection segment, where management anticipates a rebound in demand from Argentine farmers. The company has identified significant international revenue opportunities for its HB4 wheat in markets such as the US, Brazil, and Australia, which could further enhance growth despite the challenges faced in its domestic market. Additionally, the company's performance has been supported by strong sales of bio-protection products in the US and Latin America, as well as adjuvant sales in Brazil, contributing to offsetting weaknesses in its home country.

Bears say

Bioceres Crop Solutions has experienced significant revenue declines primarily due to weakened demand for its Crop Protection and Crop Nutrition solutions in Argentina, with Crop Nutrition sales down approximately 34% year-over-year. Additionally, Seed & Integrated products revenue plummeted around 75% year-over-year as the company shifted to a licensing-based business model for its HB4 program, exiting its seed production and sales activities. These factors have negatively impacted the company's overall financial performance and outlook, particularly as pressures in the Argentine market continue to affect demand and pricing.

BIOX has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bioceres Crop Solutions Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bioceres Crop Solutions Corp (BIOX) Forecast

Analysts have given BIOX a Buy based on their latest research and market trends.

According to 3 analysts, BIOX has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bioceres Crop Solutions Corp (BIOX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.